API Holdings, the parent company of Thyrocare Technologies, has announced the appointment of Rahul Guha as its new Managing Director and Chief Executive Officer, effective August 27, 2025. Guha will take on this expanded responsibility while continuing in his current role as MD & CEO of Thyrocare.
The move follows a decision by the Nomination and Remuneration Committee of API Holdings and has been cleared by the company’s board. Siddharth Shah, who previously held the MD & CEO position at API Holdings, has been re-designated as Director and Vice Chairman.
Guha brings prior experience within API Holdings, having earlier served as President of Operations. During that time, he played a key role in aligning functions across various group companies. In his new capacity, he is expected to drive long-term growth strategies and strengthen integration across the broader healthcare ecosystem, even as he continues to oversee the ongoing transformation at Thyrocare.
Thyrocare Technologies operates one of India’s largest networks of fully automated diagnostic labs. It caters to hospitals and laboratories across the country, processing over 4.6 lakh tests every night and maintaining a franchise network of over 11,000 partners.
API Holdings, founded in 2019 and based in Mumbai, operates one of India’s largest digitally integrated healthcare platforms. Its portfolio includes brands like PharmEasy, Thyrocare, Retailio, DocOn, and Aknamed—spanning online pharmacy, diagnostics, wholesale distribution, teleconsultation, and hospital supply. With additional stakes in platforms like Medlife and Marg, API Holdings supports the full spectrum of healthcare delivery, from consumers to clinics and supply chains.
